June 17, 2022
June 17, 2022 – Skyrizi® (risankizumab-rzaa – AbbVie) is now the first and only specific interleukin-23 (IL-
23) inhibitor to receive FDA approval for treating moderately to
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
News
June 17, 2022
June 17, 2022 – Comirnaty® (COVID-19 vaccine, mRNA) and Spikevax® (COVID-19 vaccine, mRNA) have been granted emergency use authorization
June 16, 2022
June 16, 2022 – The U.S. FDA has approved Imcivree® (setmelanotide – Rhythm Pharmaceuticals) to treat
of obesity and control hunger in patients who are at
June 13, 2022
June 13, 2022 – Eli Lilly has obtained FDA approval for Olumiant® (baricitinib) oral tablets to treat severe alopecia areata in adults. Olumiant is now the first FDA-approved
June 13, 2022
June 13, 2022 – AmvuttraTM (vutrisiran) has been approved to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
June 7, 2022
June 7, 2022 – CellCept® (mycophenolate mofetil) has received an expanded indication for use in recipients of allogenic heart, kidney, or liver transplants
June 7, 2022
June 7, 2022 – Regeneron’s Dupixent® (dupilumab) is now indicated to treat patients at least six months of age who have moderate-to-severe atopic dermatitis that is
June 7, 2022
June 7, 2022 – The U.S. FDA has approved an expanded indication for Sanofi’s Lantus® (insulin glargine) to improve glycemic control in adult and pediatric patients